Read our Recent Headlines


Jul 27, 2017 by Dave Sobek

July 27 Biotech Update

There is a lot to talk about today, so I will jump right into the most interesting and important news. 1. MYSTIC did not meet the primary PFS endpoint. There.

Share 0 Comments Read more
Jul 26, 2017 by Dave Sobek

July 26 Biotech Update

If there has been a consistent theme to earnings this week it has been beat and raise but with stock underperformance. This is not great in the near term as.

Jul 24, 2017 by Dave Sobek

July 24 Biotech Update

It should be a big week for news but it is starting a little slow, which is not unexpected as the earnings are clustered Tuesday through Thursday. There is some.

Jul 21, 2017 by Jason DeLorenzo

Dave-Trading August 2017

Dave Trading – August 2017 *** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued,.

Jul 21, 2017 by Dave Sobek

July 21 Biotech Update

I am back and missed all the fireworks yesterday. This week has gone quite well for the sector in terms of fundamentals and the price action reflected it. We sort.

Jul 19, 2017 by Dave Sobek

July 19 Biotech Update

The sector got a big boost from VRTX last night. If it cannot rally off of this news, then buckle your seatbelts and hedge your positions as there is unlikely.

Jul 18, 2017 by Dave Sobek

July 18 Biotech Update

There seems to be a negative pattern developing with strength early that gives way to weakness later in the day. This is not totally unexpected given the need to consolidate.

More From All Reports

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More